Pharmacokinetics, Safety, and Tolerability of NPC‐21, an Anti‐Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo‐Controlled, First‐in‐Human Phase 1 Study

NPC‐21 (EV2038) is a fully human monoclonal antibody that targets the antigenic domain 1 of glycoprotein B on the human cytomegalovirus (hCMV) envelope. NPC‐21 has been shown to have broadly neutralizing activity and to inhibit cell‐to‐cell transmission of hCMV in preclinical studies. It is currentl...

Descripción completa

Detalles Bibliográficos
Autores principales: Furihata, Kenichi, Hamada, Izumi, Niwa, Takuro, Watanabe, Tatsuya, Ezoe, Sachiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303920/
https://www.ncbi.nlm.nih.gov/pubmed/34989174
http://dx.doi.org/10.1002/cpdd.1065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303920/
https://www.ncbi.nlm.nih.gov/pubmed/34989174
http://dx.doi.org/10.1002/cpdd.1065

Ejemplares similares